Showing 1241-1250 of 5802 results for "".
Telephone Mystery Shopping and Converting New Patients
https://practicaldermatology.com/issues/april-2025/telephone-mystery-shopping-and-converting-new-patients/35621/Even with today’s market focused on online digital marketing, a practice’s biggest revenue source opportunity still seems to be the phones. The first interaction most new patients have with a practice is on the phone, which used to be about 99% of the time; now, we believe it is about 80%.Emrosi Launched in the US for Rosacea
https://practicaldermatology.com/series/dermwire-tv/emrosi-launched-in-the-us-for-rosacea/33943/In this week's DermwireTV, a new treatment for rosacea is launched in the US; long-term data is presented for tapinarof 1% cream for atopic dermatitis; and in our C-Suite Chats segment, we speak with the CEO and Co-Founder of Mama Sol.I Came In Like a Wrecking Ball
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/i-came-in-like-a-wrecking-ball/33162/I have to start by warning you, dear reader, that I am writing my first editorial for Practical Dermatology immediately after typing up four appeal letters to insurance companies.A Key to Successful Teen Acne Treatment
https://practicaldermatology.com/topics/acne-rosacea/Key-Successful-Teen-Acne-Treatment/32981/Acne has a significant psychological aspect that affects the quality of life of adolescents. The appearance of acne often causes feelings of shame, reduced self-esteem, anxiety, and even depression in young people. In some cases, it can lead to difficulties in social adaptation and social isolation,Acne and Rosacea: Dr. Harper
https://practicaldermatology.com/programs/practical-dermatology/acne-and-rosacea-dr-harper/32686/Julie Harper, MD, summarizes her presentation during the "Update 2025: Acne and Rosacea" session at Maui Derm 2025, which focused on spironolactone, oral contraceptives, and topical clascoterone.Clinical Development of Emrosi for Rosacea
https://practicaldermatology.com/series/c-suite-chats/clinical-development-emrosi-rosacea/32379/Claude Maraoui, President and CEO of Journey Medical, discusses the clinical development program for Emrosi, which was recently approved by the FDA for inflammatory lesions of rosacea in adults.Bring Pediatric Pearls Into Practice
https://practicaldermatology.com/conferences/maui-derm-2024/bring-pediatric-pearls-into-practice/20265/Resident Of Distinction Award-winner Maria Buethe, MD, PhD, a pediatric dermatology fellow at Rady Children’s Hospital in San Diego, talks about her favorite session at Maui Derm 2024 sharing technical and practice pearls for the treatment of dermatological conditions in children, including an interSkincare 2023: Year in Review
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/skincare-2023-year-in-review/24011/Practical Dermatology Co-Chief Medical Editor Joel Schlessinger, MD, shares his favorite skincare products of 2023 – and a few other insights, as well.PsA-5T-Ds: A New Psoriatic Arthritis Assessment Tool
https://practicaldermatology.com/topics/psoriasis/psa-5t-ds-a-new-psoriatic-arthritis-assessment-tool/20227/The PsA 5-Thermometer Scale Domains (PsA-5T-Ds) measures patient-reported pain, fatigue, physical function, skin problems, and depression. Here, Philip Mease, MD, discusses the validity of this tool in three Phase 3 studies of guselkumab as well as the role it could play in practice.Why is CSF Different?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/why-is-csf-different/20124/Discover why CSF is different from other meetings. Attendees and faculty share their CSF experience and describe why they think the meeting and its new Nashville home make for “a great program.”